Bruno Gagnon
Corporate Officer/Principal bij OPTHEA LIMITED
Profiel
Bruno Gagnon is a professional with experience in various firms.
He is currently working as Senior Vice President-Global Clinical Operations at Opthea Ltd.
He has previously worked as Vice President-Clinical Operations at BioMarin Pharmaceutical, Inc. and as Senior Vice President-Development Operations at Eidos Therapeutics, Inc. Mr. Gagnon has completed his graduate degree from the University of Montréal and his undergraduate degree from Université Laval.
Actieve functies van Bruno Gagnon
| Bedrijven | Functie | Begin |
|---|---|---|
| OPTHEA LIMITED | Corporate Officer/Principal | 01-07-2022 |
Eerdere bekende functies van Bruno Gagnon
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Operationeel Directeur | - |
| EIDOS THERAPEUTICS, INC. | Operationeel Directeur | - |
Opleiding van Bruno Gagnon
| University of Montréal | Graduate Degree |
| Université Laval | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| OPTHEA LIMITED | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |